What did Deutsche Bank do in the March 06, 2026 LLY analyst rating update?

Deutsche Bank reiterated a **Buy** rating on Eli Lilly and Company (**LLY**) on March 06, 2026. The firm did not issue a new price target and the market reaction was modest, about **0.44% ($4.31)** since the note.

Does a maintained Buy change an investor's position in LLY?

A maintained Buy typically reinforces existing long positions but is not a fresh buy signal. Investors should use the LLY analyst rating as confirmation and also review valuation, recent news, and risk tolerance before changing position sizes.

Were any price targets issued with this LLY analyst rating?

No. Deutsche Bank’s March 06, 2026 note reiterated a Buy on **LLY** without publishing a new price target, according to StreetInsider coverage of the analyst note.

How does Meyka AI view the LLY analyst rating?

Meyka AI tracks the maintained Buy as part of real-time coverage and assigns **LLY** a grade of **A** based on benchmark and sector metrics, financial growth, and analyst consensus. Grades are informational and not investment advice.

Analyst Ratings

Deutsche Bank Maintains Buy on Eli Lilly and Company (LLY) March 06, 2026

ByDanny Kontos March 7, 2026

Deutsche Bank on March 06, 2026 maintained its Buy rating on Eli Lilly and Company (LLY). This is the main LLY analyst rating update today and the note followed aggregated prescription script data. StreetInsider reported the reiteration and a modest market move of 0.44% ($4.31) since the call. The firm did not publish a new price target. As an AI-powered market analysis platform, Meyka AI tracks this action as part of real-time coverage for investors weighing pharma exposure.